Curis Lifesciences Q2 FY26 – Strong Growth in Revenue and Profit, EPS Impacted by Dilution

Curis Lifesciences reported a strong September 2025 quarter, with solid YoY growth across sales, operating profit, and net earnings. EPS, however, declined sharply due to capital structure changes or expanded share base. • Sales: ↑ 76% YoY to ₹27.9 crore (vs ₹15.9 crore in Sep 2024) • EBIDT: ↑ 57% YoY to ₹5.99 crore (vs ₹3.81 crore) • Net Profit: ↑ 90% YoY to ₹4.21 crore (vs ₹2.20 crore) • EPS: ↓ 84% YoY to ₹7.09 (vs ₹44.00) At a price of ₹125, market cap ₹101 crore, and PE 12.3, Curis Lifesciences continues to demonstrate strong operating momentum despite EPS compression.